Over the last two decades interest in the pharmacodynamic and pharmacokinetic properties of the enantiomers of racemic chiral drugs has increased considerably and has become an issue of concern to both the pharmaceutical industry and the regulatory authorities . This current interest has been stimulated not only in part by the “Thalidomide case” (marketed under the trade name Contergan® in Germany), but also by the recent advances in stereoselective synthesis and stereospecific analysis, particularly in the area of chromatography. As a result of the technological advances in the latter areas it is likely that new drug development will concentrate on single stereoisomers and the development of racemic mixtures will require scientific justification. In the current regulatory climate there appears to be a continuing requirement for enantiospecific analysis and thus modern drug development presents a considerable challenge for the pharmaceutical analyst and separation scientist . As a consequence, enantiospecific analytical methodologies are required throughout the drug discovery/development process. However, in the present volume, we cannot cover this rapidly developing field. The reader interested in these aspects should refer to [2–5]. Herein, we confine ourselves to enantioselective toxic and ecotoxic effects as observed for chiral drugs. This aspect appears to be of increasing concern because, as shown by the recent investigations by Weigel, drugs are being found in the aquatic environment in larger concentrations than previously expected .
Weitere Kapitel dieses Buchs durch Wischen aufrufen
- Enantioselective Toxic and Ecotoxic Effects of Drugs and Environmental Pollutants
- Springer Berlin Heidelberg
Systemische Notwendigkeit zur Weiterentwicklung von Hybridnetzen